推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

EUROPEAN JOURNAL OF CANCER

2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 EUR J CANCER最新评论:under review1个多月,不知道结果如何 (2024-06-25)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


EUROPEAN JOURNAL OF CANCER期刊基本信息Hello,您是该期刊的第88233位访客


基本信息 登录收藏
期刊名字EUROPEAN JOURNAL OF CANCEREUROPEAN JOURNAL OF CANCER

EUR J CANCER
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
8.5
51人评分
我要评分

声誉
9.4

影响力
8.1

速度
7.0

期刊ISSN0959-8049
微信扫码收藏此期刊
E-ISSN1879-0852
2023-2024最新影响因子
(数据来源于搜索引擎)
7.6 点击查看影响因子趋势图
实时影响因子 截止2024年3月26日:7.098
2023-2024自引率2.60%点击查看自引率趋势图
五年影响因子7.7
JCI期刊引文指标 1.68
h-index 193
CiteScore
2024年最新版
CiteScoreSJRSNIPCiteScore排名
11.502.5011.994
学科分区排名百分位
大类:Medicine
小类:Oncology
Q147 / 404
大类:Medicine
小类:Cancer Research
Q140 / 230

期刊简介
The European Journal of Cancer (including EJC Supplements), is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), translational oncology, and on cancer epidemiology and prevention. The Journal now has online submission for authors.
期刊官方网站http://www.ejcancer.info/
期刊投稿网址https://www.editorialmanager.com/EJC
期刊语言要求Language
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service.

经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足EUROPEAN JOURNAL OF CANCER的语言要求,还能让EUROPEAN JOURNAL OF CANCER编辑和审稿人得到更好的审稿体验,让稿件最大限度地被EUROPEAN JOURNAL OF CANCER编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(1篇)
提交文稿
是否OA开放访问Yes
通讯方式ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB
出版商Elsevier Ltd
涉及的研究方向医学-肿瘤学
出版国家或地区ENGLAND
出版语言English
出版周期Semimonthly
出版年份1990
年文章数 318点击查看年文章数趋势图
Gold OA文章占比39.56%
研究类文章占比:
文章 ÷(文章 + 综述)
90.25%
WOS期刊SCI分区
2023-2024年最新版
WOS分区等级:1区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ138/322
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:ONCOLOGYSCIEQ134/322
中国科学院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2023年12月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 2区1区4区
ONCOLOGY
肿瘤学
2区1区2区
中国科学院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 3区1区3区
ONCOLOGY
肿瘤学
2区3区2区
中国科学院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 3区1区4区
ONCOLOGY
肿瘤学
3区2区2区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0959-8049%5BISSN%5D
平均审稿速度网友分享经验:
平均1.0个月
来源Elsevier官网:
平均5.3周
平均录用比例网友分享经验:
约28%
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在EUROPEAN JOURNAL OF CANCER顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
在线出版周期来源Elsevier官网:
平均7.3周
期刊常用信息链接
同领域相关期刊 EUROPEAN JOURNAL OF CANCER期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 EUROPEAN JOURNAL OF CANCER中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
EUROPEAN JOURNAL OF CANCER上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    Nature Reviews Clinical Oncology12799.40
    NATURE REVIEWS CANCER396111.90
    ANNALS OF ONCOLOGY21063.90
    CANCER CELL29555.20
    JOURNAL OF CLINICAL ONCOLOGY49441.20
    LANCET ONCOLOGY27462.10
    CANCER RESEARCH41116.10
    SEMINARS IN CANCER BIOLOGY13426.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH6718.20
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE626889
    BIOMATERIALS532052
    BIOMEDICINE & PHARMACOTHERAPY493350
    Journal of Materials Chemistry B474024
    Frontiers in Pharmacology473255
    Frontiers in Immunology446572
    JOURNAL OF ETHNOPHARMACOLOGY425770
    COLLOIDS AND SURFACES B-BIOINTERFACES416046
    COMPUTERS IN BIOLOGY AND MEDICINE406426
    Frontiers in Oncology402778
  •  

    EUROPEAN JOURNAL OF CANCER EUROPEAN JOURNAL OF CANCER
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer

    Author: Xu, Jianming; Ying, Jieer; Liu, Rongrui; Wu, Jun; Ye, Feng; Xu, Nong; Zhang, Yanqiao; Zhao, Rusen; Xiang, Xiaojun; Wang, Jianhong; Lin, Xiaoyan; Xu, Huiting; Gao, Shegan; Luo, Suxia; Guo, Baohong; Li, Xionghui; Su, Yangzhi; Wang, Qian
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 1-12. DOI: 10.1016/j.ejca.2022.10.004
        PubMed      DOI
    2.Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer

    Author: Swain, Sandra M.; Tan, Antoinette R.; Gianni, Luca; Kuemmel, Sherko; Dang, Chau T.; Schneeweiss, Andreas; O'Shaughnessy, Joyce; Liu, Haiying; Aguila, Christian; Heeson, Sarah; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora; Loibl, Sibylle
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 70-81. DOI: 10.1016/j.ejca.2022.09.024
        PubMed      DOI
    3.Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)

    Author: Sheng, Xinan; Ye, DingWei; Zhou, Aiping; Yao, Xin; Luo, Hong; He, Zhisong; Wang, Zengjun; Zhao, Yingchao; Ji, Zhigang; Zou, Qing; He, Chaohong; Guo, Jianming; Tu, Xinhua; Liu, Ziling; Shi, Benkang; Liu, Ben; Chen, Peng; Wei, Qiang; Hu, Zhiquan; Zhang, Yanqiao; Jiang, Kui; Zhou, Fangjian; Wu, Dapeng; Fu, Cheng; Li, Xingya; Wu, Bin; Wang, Lijie; Qin, Shukui; Li, Gang; Liu, Yunpeng; Guo, Hongqian; Chen, Kehe; Zhang, Dahong; Wang, Gongxian; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Guo, Jun
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 178, Issue , pp. 205-215. DOI: 10.1016/j.ejca.2022.10.025
        PubMed      DOI
    4.Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases

    Author: Guo, Ye; Zhang, Weijie; Ying, Jieer; Zhang, Yanqiao; Pan, Yueyin; Qiu, Wensheng; Fan, Qingxia; Xu, Qi; Ma, Yue; Wang, Gang; Guo, Jing; Su, Weiguo; Fan, Songhua; Tan, Panfeng; Wang, Yan; Luo, Yang; Zhou, Hui; Li, Jin
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 181, Issue , pp. 26-37. DOI: 10.1016/j.ejca.2022.12.004
        PubMed      DOI
    5.Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    Author: Cueva, Juan F.; Palacio, Isabel; Churruca, Cristina; Herrero, Ana; Pardo, Beatriz; Constenla, Manuel; Santaballa, Ana; Manso, Luis; Estevez, Purificacin; Maximiano, Constanza; Legeren, Marta; Marquina, Gloria; de Juan, Ana; Quindos, Maria; Sanchez, Luisa; Barquin, Arantzazu; Fernandez, Isaura; Martin, Cristina; Juarez, Asuncin; Martin, Teresa; Garcia, Yolanda; Yubero, Alfonso; Gallego, Alejandro; Bueno, Alejandro Martinez; Guerra, Eva; Gonzalez-Martin, Antonio
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 3-14. DOI: 10.1016/j.ejca.2022.12.023
        PubMed      DOI
    6.Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial

    Author: Wang, Xuan; Wu, Xiaowen; Yang, Yue; Xu, Weiran; Tian, Hui; Lian, Bin; Chi, Zhihong; Si, Lu; Sheng, Xinan; Kong, Yan; Zhou, Li; Mao, Lili; Li, Siming; Tang, Bixia; Yan, Xieqiao; Bai, Xue; Guo, Jun; Cui, ChuanLiang
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 182, Issue , pp. 57-65. DOI: 10.1016/j.ejca.2022.12.027
        PubMed      DOI
    7.First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

    Author: Reck, Martin; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Cheng, Ying; Sakai, Hiroshi; Paz-Ares, Luis; Lu, Shun; John, Thomas; Sun, Xiaowu; Moisei, Aniela; Taylor, Fiona; Lawrance, Rachael; Zhang, Xiaoqing; Sylvester, Judi; Yuan, Yong; Blum, Steven I.; Penrod, John R.; Carbone, David P.
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 183, Issue , pp. 174-187. DOI: 10.1016/j.ejca.2023.01.015
        PubMed      DOI
    8.OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Author: Robson, Mark E.; Im, Seock-Ah; Senkus, Elzbieta; Xu, Binghe; Domchek, Susan M.; Masuda, Norikazu; Delaloge, Suzette; Tung, Nadine; Armstrong, Anne; Dymond, Mike; Fielding, Anitra; Allen, Allison; Conte, Pierfranco
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 184, Issue , pp. 39-47. DOI: 10.1016/j.ejca.2023.01.031
        PubMed      DOI
    9.Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2-advanced breast cancer (FRIEND study)

    Author: Wang, Jiayu; Cai, Li; Song, Yanqiu; Sun, Tao; Tong, Zhongsheng; Teng, Yuee; Li, Huiping; Ouyang, Quchang; Chen, Qianjun; Cui, Shude; Yin, Yongmei; Liao, Ning; Sun, Qiang; Feng, Jifeng; Wang, Xiaojia; Xu, Binghe
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 184, Issue , pp. 73-82. DOI: 10.1016/j.ejca.2023.02.007
        PubMed      DOI
    10.Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose-response meta-analysis

    Author: Yan, Lun-Jie; Yang, Long-Shan; Yan, Yu-Chuan; Tan, Si-Yu; Ding, Zi-Niu; Liu, Hui; Wang, Dong-Xu; Li, Tao
    Journal: EUROPEAN JOURNAL OF CANCER. 2023; Vol. 185, Issue , pp. 150-163. DOI: 10.1016/j.ejca.2023.03.005
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Disease Primers4876.70
    NATURE REVIEWS CANCER396111.90
    NATURE REVIEWS IMMUNOLOGY35193.40
    同分区等级的其他期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    NATURE REVIEWS MOLECULAR CELL BIOLOGY386173.60
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Materials61119.40
    Nature Reviews Disease Primers4876.70
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共156条 (包含回复)

我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室